Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer and Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial Using veliparib, paclitaxel, carboplatin, pharmacological study and laboratory biomarker analysis

- The folks at National Cancer Institute (NCI) are studying the effects of veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis on Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer and Unspecified Adult Solid Tumor, Protocol Specific in individuals ages 18 years and older. This clinical trial is slated to start January 2011.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors."

Locations

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania - Recruiting

University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.